Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Arcus Biosciences Inc (RCUS)

Arcus Biosciences Inc (RCUS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,319,539
  • Shares Outstanding, K 64,906
  • Annual Sales, $ 15,000 K
  • Annual Income, $ -84,710 K
  • 60-Month Beta 1.32
  • Price/Sales 84.38
  • Price/Cash Flow N/A
  • Price/Book 2.68
Trade RCUS with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 0.35
  • Number of Estimates 3
  • High Estimate 1.96
  • Low Estimate -0.67
  • Prior Year -0.51
  • Growth Rate Est. (year over year) +168.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.69 +20.67%
on 10/02/20
21.15 -4.78%
on 10/19/20
+2.48 (+14.04%)
since 09/23/20
3-Month
16.69 +20.67%
on 10/02/20
25.48 -20.96%
on 08/19/20
-2.91 (-12.62%)
since 07/23/20
52-Week
7.19 +180.11%
on 11/18/19
37.41 -46.16%
on 05/21/20
+11.59 (+135.56%)
since 10/23/19

Most Recent Stories

More News
Infinity's Eganelisib Gets Fast Track Tag for Breast Cancer

Infinity's (INFI) eganelisib, combined with a checkpoint inhibitor and chemotherapy, gets Fast Track designation by the FDA for the treatment of inoperable locally-advanced or metastatic TNBC in the first-line...

RHHBY : 41.0300 (+0.20%)
BMY : 60.13 (-1.04%)
INFI : 1.1800 (unch)
RCUS : 20.14 (-0.93%)
Gilead Expands Collaboration With Tango for Cancer Therapies

Gilead (GILD) expands its partnership with biotech company, Tango, for innovative targeted immune evasion cancer therapies.

ALXN : 121.61 (+1.62%)
RHHBY : 41.0300 (+0.20%)
GILD : 60.79 (+0.20%)
RCUS : 20.14 (-0.93%)
Is Arcus Biosciences (RCUS) Stock Outpacing Its Medical Peers This Year?

Is (RCUS) Outperforming Other Medical Stocks This Year?

RCUS : 20.14 (-0.93%)
Gilead's Rating Upgraded on Potential Coronavirus Drug Sales

Gilead (GILD) rides high on potential sales from its experimental coronavirus treatment, remdesivir, and collaboration with Arcus.

GILD : 60.79 (+0.20%)
GSK : 35.29 (+0.57%)
GLPG : 127.65 (+3.21%)
RCUS : 20.14 (-0.93%)
Arcus Biosciences (RCUS) Catches Eye: Stock Jumps 5.4%

Arcus Biosciences (RCUS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

AKCA : 18.17 (+0.17%)
RCUS : 20.14 (-0.93%)
Gilead Sciences and Arcus Biosciences Establish 10-year Partnership to Co-develop and Co-commercialize Next-generation Cancer Immunotherapies

--- Gilead Gains Broad Access to Arcus's Clinical and Preclinical Pipeline of Immuno-Oncology Product Candidates that Target Critical Biological Pathways -

GILD : 60.79 (+0.20%)
RCUS : 20.14 (-0.93%)
Infinity (INFI) Q1 Earnings Lag Estimates, IPI-549 in Focus

Infinity (INFI) posts a wider-than-expected loss for the first quarter of 2020.

RHHBY : 41.0300 (+0.20%)
BMY : 60.13 (-1.04%)
INFI : 1.1800 (unch)
RCUS : 20.14 (-0.93%)
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2020

Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate...

SURF : 9.57 (+8.38%)
RCUS : 20.14 (-0.93%)
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Misses Revenue Estimates

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -12.50% and -12.50%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?...

RCUS : 20.14 (-0.93%)
Is Arcus Biosciences (RCUS) Outperforming Other Medical Stocks This Year?

Is (RCUS) Outperforming Other Medical Stocks This Year?

RCUS : 20.14 (-0.93%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in...

See More

Key Turning Points

2nd Resistance Point 20.99
1st Resistance Point 20.57
Last Price 20.14
1st Support Level 19.72
2nd Support Level 19.29

See More

52-Week High 37.41
Fibonacci 61.8% 25.87
Fibonacci 50% 22.30
Last Price 20.14
Fibonacci 38.2% 18.73
52-Week Low 7.19

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar